TCRX
TScan Therapeutics, Inc.
Price Chart
Latest Quote
$0.92
+0.02 (+2.23%)
Current Price
| Previous Close | $0.90 |
| Open | $0.91 |
| Day High | $0.93 |
| Day Low | $0.87 |
| Volume | 283,681 |
Stock Information
| Shares Outstanding | 61.07M |
| Total Debt | $92.54M |
| Cash Equivalents | $128.06M |
| Revenue | $9.14M |
| Net Income | $-124.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $60.12M |
| EPS (TTM) | $-0.96 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $19.90M |
| Sales | $9.14M |
| Income | $-124.31M |
| Book/sh | $2.16 |
| Cash/sh | $2.10 |
| Employees | 138 |
Financial Ratios
| Quick Ratio | 6.41 |
| Current Ratio | 6.65 |
| Debt/Eq | 95.48 |
Returns & Margins
| ROA | -29.62% |
| ROE | -80.95% |
| Operating Margin | -2967.31% |
Ownership
| Insider Ownership | 0.20% |
| Institutional Ownership | 59.50% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.04 |
| P/S | 6.58 |
| P/B | 0.43 |
Analyst Data
| Recommendation | none |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $0.98 |
| SMA50 | $1.09 |
| SMA200 | $1.27 |
| RSI | 34.31 |
| ATR | 0.0739 |
| Shares Float | 55.39M |
| Short Float | 2.09% |
| Short Ratio | 1.43 |
| Volatility | 1.03 |
| Rel Volume | 0.95 |
Performance History
| Week | -0.43% |
| Month | -4.47% |
| Quarter | -11.54% |
| 6 Months | -3.36% |
| YTD | -9.80% |
| Year | -40.26% |
| 3 Years | -65.41% |
| 10 Years | -91.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.92 | 406,285 |
| 2026-06-17 | $0.90 | 555,700 |
| 2026-06-16 | $0.85 | 812,300 |
| 2026-06-15 | $0.95 | 646,300 |
| 2026-06-12 | $0.91 | 380,100 |
| 2026-06-11 | $0.92 | 355,000 |
| 2026-06-10 | $0.92 | 288,800 |
| 2026-06-09 | $0.97 | 326,800 |
| 2026-06-08 | $0.99 | 240,800 |
| 2026-06-05 | $0.98 | 313,000 |
| 2026-06-04 | $1.02 | 406,800 |
| 2026-06-03 | $0.97 | 446,600 |
| 2026-06-02 | $0.98 | 486,100 |
| 2026-06-01 | $1.01 | 486,100 |
| 2026-05-29 | $1.08 | 203,800 |
| 2026-05-28 | $1.08 | 293,700 |
| 2026-05-27 | $1.07 | 507,300 |
| 2026-05-26 | $1.07 | 535,000 |
| 2026-05-22 | $1.06 | 676,300 |
| 2026-05-21 | $1.02 | 224,200 |
| 2026-05-20 | $1.00 | 587,300 |
| 2026-05-19 | $0.96 | 598,800 |
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
đ° Latest News
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
Insider Monkey âĸ 2026-06-02T13:57:37Z
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T12:25:09Z
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
Insider Monkey âĸ 2026-03-25T19:35:36Z
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-04T13:15:02Z
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-02-25T17:15:09Z
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-02-12T12:40:01Z
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Zacks âĸ 2026-02-11T12:25:00Z
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2026-02-06T13:15:02Z
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-12T13:25:02Z
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-11-10T22:10:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $10,325,000 | $2,816,000 | $21,049,000 | $13,535,000 |
| Operating Revenue | $10,325,000 | $2,816,000 | $21,049,000 | $13,535,000 |
| Expenses | ||||
| Interest Expense | $2,769,000 | $3,653,000 | $3,759,000 | $1,176,000 |
| Total Expenses | $146,138,000 | $137,637,000 | $114,507,000 | $80,171,000 |
| Net Non Operating Interest Income Expense | $6,047,000 | $8,412,000 | $4,240,000 | $415,000 |
| Interest Expense Non Operating | $2,769,000 | $3,653,000 | $3,759,000 | $1,176,000 |
| Operating Expense | $146,138,000 | $137,637,000 | $114,507,000 | $80,171,000 |
| General And Administrative Expense | $31,332,000 | $29,559,000 | $25,492,000 | $20,352,000 |
| Other Income Expense | - | $-1,090,000 | - | - |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Net Interest Income | $6,047,000 | $8,412,000 | $4,240,000 | $415,000 |
| Interest Income | $8,816,000 | $12,065,000 | $7,999,000 | $1,591,000 |
| Normalized Income | $-129,766,000 | $-126,409,000 | $-89,218,000 | $-66,221,000 |
| Net Income From Continuing And Discontinued Operation | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Total Operating Income As Reported | $-135,813,000 | $-134,821,000 | $-93,458,000 | $-66,636,000 |
| Net Income Common Stockholders | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Net Income | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Net Income Including Noncontrolling Interests | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Net Income Continuous Operations | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Pretax Income | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Special Income Charges | $0 | $-1,090,000 | $0 | - |
| Interest Income Non Operating | $8,816,000 | $12,065,000 | $7,999,000 | $1,591,000 |
| Operating Income | $-135,813,000 | $-134,821,000 | $-93,458,000 | $-66,636,000 |
| Depreciation Amortization Depletion Income Statement | $656,000 | $728,000 | $862,000 | - |
| Depreciation And Amortization In Income Statement | $656,000 | $728,000 | $862,000 | - |
| Depreciation Income Statement | $656,000 | $728,000 | $862,000 | - |
| Per Share | ||||
| Diluted EPS | $-1.00 | $-1.14 | $-1.36 | $-2.75 |
| Basic EPS | $-1.00 | $-1.14 | $-1.36 | $-2.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-124,131,000 | $-118,648,000 | $-80,098,000 | $-59,908,000 |
| Total Unusual Items | $0 | $-1,090,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-1,090,000 | $0 | - |
| Reconciled Depreciation | $2,866,000 | $4,108,000 | $5,361,000 | $5,137,000 |
| EBITDA (Bullshit earnings) | $-124,131,000 | $-119,738,000 | $-80,098,000 | $-59,908,000 |
| EBIT | $-126,997,000 | $-123,846,000 | $-85,459,000 | $-65,045,000 |
| Diluted Average Shares | $129,777,415 | $111,990,417 | $65,599,858 | $24,048,267 |
| Basic Average Shares | $129,777,415 | $111,990,417 | $65,599,858 | $24,048,267 |
| Diluted NI Availto Com Stockholders | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Research And Development | $114,150,000 | $107,350,000 | $88,153,000 | $59,819,000 |
| Selling General And Administration | $31,332,000 | $29,559,000 | $25,492,000 | $20,352,000 |
| Other Gand A | $14,175,000 | $13,956,000 | $14,095,000 | $8,698,000 |
| Salaries And Wages | $17,157,000 | $15,603,000 | $11,397,000 | $11,654,000 |
| Other Special Charges | - | $1,090,000 | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $123,123,000 | $240,970,000 | $150,867,000 | $99,434,000 |
| Total Assets | $228,789,000 | $371,118,000 | $272,149,000 | $199,091,000 |
| Total Non Current Assets | $71,581,000 | $78,396,000 | $77,912,000 | $74,964,000 |
| Other Non Current Assets | $5,132,000 | $6,797,000 | $6,678,000 | $5,762,000 |
| Current Assets | $157,208,000 | $292,722,000 | $194,237,000 | $124,127,000 |
| Other Current Assets | $4,802,000 | $2,612,000 | $2,193,000 | $4,100,000 |
| Cash Cash Equivalents And Short Term Investments | $152,406,000 | $290,110,000 | $192,044,000 | $120,027,000 |
| Cash And Cash Equivalents | $152,406,000 | $178,689,000 | $133,359,000 | $120,027,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $94,138,000 | $97,381,000 | $92,433,000 | $85,984,000 |
| Long Term Debt And Capital Lease Obligation | $86,971,000 | $92,811,000 | $85,840,000 | $82,303,000 |
| Long Term Debt | $32,534,000 | $32,072,000 | $26,700,000 | $29,290,000 |
| Current Debt And Capital Lease Obligation | $7,167,000 | $4,570,000 | $6,593,000 | $3,681,000 |
| Current Debt | - | - | $3,347,000 | - |
| Other Current Borrowings | - | - | $3,347,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $105,666,000 | $130,148,000 | $121,282,000 | $99,657,000 |
| Total Non Current Liabilities Net Minority Interest | $86,971,000 | $94,192,000 | $91,462,000 | $82,352,000 |
| Non Current Deferred Liabilities | $0 | $1,246,000 | $5,622,000 | $0 |
| Current Liabilities | $18,695,000 | $35,956,000 | $29,820,000 | $17,305,000 |
| Other Current Liabilities | $196,000 | $76,000 | $425,000 | $431,000 |
| Current Deferred Liabilities | $2,619,000 | $11,698,000 | $10,137,000 | $3,874,000 |
| Payables And Accrued Expenses | $4,568,000 | $12,767,000 | $7,187,000 | $4,962,000 |
| Payables | $1,241,000 | $4,278,000 | $2,374,000 | $2,912,000 |
| Accounts Payable | $1,241,000 | $4,278,000 | $2,374,000 | $2,912,000 |
| Other Non Current Liabilities | - | $135,000 | - | $49,000 |
| Equity | ||||
| Common Stock Equity | $123,123,000 | $240,970,000 | $150,867,000 | $99,434,000 |
| Total Equity Gross Minority Interest | $123,123,000 | $240,970,000 | $150,867,000 | $99,434,000 |
| Stockholders Equity | $123,123,000 | $240,970,000 | $150,867,000 | $99,434,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $51,000 | $0 | - |
| Retained Earnings | $-504,862,000 | $-375,096,000 | $-247,597,000 | $-158,379,000 |
| Other Equity Adjustments | - | $51,000 | - | - |
| Other | ||||
| Ordinary Shares Number | $56,901,623 | $56,590,627 | $47,829,529 | $24,225,954 |
| Share Issued | $56,901,623 | $56,590,627 | $47,829,529 | $24,225,954 |
| Tangible Book Value | $123,123,000 | $240,970,000 | $150,867,000 | $99,434,000 |
| Invested Capital | $155,657,000 | $273,042,000 | $180,914,000 | $128,724,000 |
| Working Capital | $138,513,000 | $256,766,000 | $164,417,000 | $106,822,000 |
| Capital Lease Obligations | $61,604,000 | $65,309,000 | $62,386,000 | $56,694,000 |
| Total Capitalization | $155,657,000 | $273,042,000 | $177,567,000 | $128,724,000 |
| Additional Paid In Capital | $627,979,000 | $616,009,000 | $398,459,000 | $257,810,000 |
| Capital Stock | $6,000 | $6,000 | $5,000 | $3,000 |
| Common Stock | $6,000 | $6,000 | $5,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Non Current Deferred Revenue | $0 | $1,246,000 | $5,622,000 | $0 |
| Long Term Capital Lease Obligation | $54,437,000 | $60,739,000 | $59,140,000 | $53,013,000 |
| Current Deferred Revenue | $2,619,000 | $11,698,000 | $10,137,000 | $3,874,000 |
| Current Capital Lease Obligation | $7,167,000 | $4,570,000 | $3,246,000 | $3,681,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,145,000 | $6,845,000 | $5,478,000 | $4,357,000 |
| Current Accrued Expenses | $3,327,000 | $8,489,000 | $4,813,000 | $2,050,000 |
| Net PPE | $66,449,000 | $71,599,000 | $71,234,000 | $69,202,000 |
| Accumulated Depreciation | $-21,570,000 | $-18,704,000 | $-14,597,000 | $-10,220,000 |
| Gross PPE | $88,019,000 | $90,303,000 | $85,831,000 | $79,422,000 |
| Leases | $5,391,000 | $3,258,000 | $3,159,000 | $3,447,000 |
| Construction In Progress | $118,000 | $100,000 | $548,000 | $5,000 |
| Other Properties | $79,293,000 | $83,728,000 | $79,145,000 | $13,747,000 |
| Machinery Furniture Equipment | $3,217,000 | $3,217,000 | $2,979,000 | $62,223,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $111,421,000 | $58,685,000 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-139,726,000 | $-114,647,000 | $-64,504,000 | $-70,728,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-135,319,000 | $-110,822,000 | $-61,358,000 | $-66,503,000 |
| Cash Flow From Continuing Operating Activities | $-135,319,000 | $-110,822,000 | $-61,358,000 | $-66,503,000 |
| Operating Gains Losses | - | $1,090,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-4,407,000 | $-3,825,000 | $-3,146,000 | $-4,225,000 |
| Investing Cash Flow | $109,372,000 | $-52,613,000 | $-60,759,000 | $-4,225,000 |
| Cash Flow From Continuing Investing Activities | $109,372,000 | $-52,613,000 | $-60,759,000 | $-4,225,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $33,131,000 | $42,414,000 | $193,000 |
| Financing Cash Flow | $-336,000 | $208,765,000 | $135,443,000 | $29,356,000 |
| Cash Flow From Continuing Financing Activities | $-336,000 | $208,765,000 | $135,443,000 | $29,356,000 |
| Net Other Financing Charges | $-400,000 | - | - | $-324,000 |
| Cash Dividends Paid | $0 | $0 | - | - |
| Net Common Stock Issuance | $0 | $33,131,000 | $42,414,000 | $193,000 |
| Common Stock Issuance | $0 | $33,131,000 | $42,414,000 | $193,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-17,144,000 | $0 | - |
| Issuance Of Debt | $0 | $32,457,000 | $0 | $29,354,000 |
| Interest Paid Supplemental Data | $2,307,000 | $2,881,000 | $3,002,000 | $660,000 |
| End Cash Position | $157,437,000 | $183,720,000 | $138,390,000 | $125,064,000 |
| Beginning Cash Position | $183,720,000 | $138,390,000 | $125,064,000 | $166,436,000 |
| Changes In Cash | $-26,283,000 | $45,330,000 | $13,326,000 | $-41,372,000 |
| Interest Paid Cff | $-200,000 | $0 | - | - |
| Proceeds From Stock Option Exercised | $264,000 | $160,321,000 | $93,029,000 | $133,000 |
| Net Issuance Payments Of Debt | $0 | $15,313,000 | $0 | $29,354,000 |
| Net Long Term Debt Issuance | $0 | $15,313,000 | $0 | $29,354,000 |
| Long Term Debt Payments | $0 | $-17,144,000 | $0 | - |
| Long Term Debt Issuance | $0 | $32,457,000 | $0 | $29,354,000 |
| Net Investment Purchase And Sale | $113,779,000 | $-48,788,000 | $-57,613,000 | $0 |
| Sale Of Investment | $201,250,000 | $192,657,000 | $20,000,000 | $0 |
| Purchase Of Investment | $-87,471,000 | $-241,445,000 | $-77,613,000 | $0 |
| Net PPE Purchase And Sale | $-4,407,000 | $-3,825,000 | $-3,146,000 | $-4,225,000 |
| Purchase Of PPE | $-4,407,000 | $-3,825,000 | $-3,146,000 | $-4,225,000 |
| Change In Working Capital | $-18,178,000 | $5,054,000 | $17,606,000 | $-10,230,000 |
| Change In Other Working Capital | $-7,416,000 | $-934,000 | $12,820,000 | $-11,080,000 |
| Change In Payables And Accrued Expense | $-10,237,000 | $6,526,000 | $3,801,000 | $1,260,000 |
| Change In Accrued Expense | $-7,226,000 | $4,532,000 | $3,853,000 | $732,000 |
| Change In Payable | $-3,011,000 | $1,994,000 | $-52,000 | $528,000 |
| Change In Account Payable | $-3,011,000 | $1,994,000 | $-52,000 | $528,000 |
| Change In Prepaid Assets | $-525,000 | $-538,000 | $985,000 | $-410,000 |
| Other Non Cash Items | $462,000 | $773,000 | $757,000 | $260,000 |
| Stock Based Compensation | $11,706,000 | $9,549,000 | $5,208,000 | $4,551,000 |
| Amortization Of Securities | $-2,409,000 | $-3,897,000 | $-1,072,000 | $0 |
| Depreciation Amortization Depletion | $2,866,000 | $4,108,000 | $5,361,000 | $5,137,000 |
| Depreciation And Amortization | $2,866,000 | $4,108,000 | $5,361,000 | $5,137,000 |
| Depreciation | $2,866,000 | $4,108,000 | $5,361,000 | $5,137,000 |
| Net Income From Continuing Operations | $-129,766,000 | $-127,499,000 | $-89,218,000 | $-66,221,000 |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-16